Takeda Pharmaceutical Co Ltd
Close on Nov 20, 2026Market cap $75.03BP/E –Yield –
Takeda Pharmaceutical Net Cash from Operating Activities (Operating Cash Flow by Quarter
Net Cash from Operating Activities (Operating Cash Flow — Exhibit 99.1)
Takeda Pharmaceutical Net Cash from Operating Activities (Operating Cash Flow: 304.30 JPY billion in Q2 FY27, down 19.6% from a year earlier.
Where the Q2 FY27 figure comes from
Calculated from reported figures: Q2 = 6M year-to-date − Q1 (YTD − prior YTD)
Source: SEC EDGAR Filing (exhibit991_102926.htm) ↗
Reported in Form 6-K Exhibit 99.1 Quarterly Financial Appendix.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net Cash from Operating Activities (Operating Cash Flow — Exhibit 99.1) | Year on year | Source |
|---|---|---|---|---|
| Q2 FY27CQ3 2026 | Sep 30, 2026 | 304.30 | -19.6% | SEC EDGAR Filing (exhibit991_102926.htm) ↗ |
| Q1 FY27CQ2 2026 | Jun 30, 2026 | 127.60 | -40.8% | SEC EDGAR Filing (exhibit991_073026.htm) ↗ |
| Q4 FY26CQ1 2026 | Mar 31, 2026 | 74.50 | -66.5% | SEC EDGAR Filing (exhibit991.htm) ↗ |
| Q3 FY26CQ4 2025 | Dec 31, 2025 | 373.20 | -2.7% | SEC EDGAR Filing (exhibit991_012926.htm) ↗ |
| Q2 FY26CQ3 2025 | Sep 30, 2025 | 378.30 | +34.6% | SEC EDGAR Filing (exhibit991_102926.htm) ↗ |
| Q1 FY26CQ2 2025 | Jun 30, 2025 | 215.40 | +26.5% | SEC EDGAR Filing (exhibit991_073025.htm) ↗ |
| Q4 FY25CQ1 2025 | Mar 31, 2025 | 222.20 | -20.2% | SEC EDGAR Filing (exhibit991.htm) ↗ |
| Q3 FY25CQ4 2024 | Dec 31, 2024 | 383.70 | +161.9% | SEC EDGAR Filing (exhibit991_012926.htm) ↗ |
| Q2 FY25CQ3 2024 | Sep 30, 2024 | 281.00 | +41.3% | SEC EDGAR Filing (exhibit991_103025.htm) ↗ |
| Q1 FY25CQ2 2024 | Jun 30, 2024 | 170.30 | +84.3% | SEC EDGAR Filing (exhibit991_073124.htm) ↗ |
| Q4 FY24CQ1 2024 | Mar 31, 2024 | 278.50 | -5.2% | SEC EDGAR Filing (exhibit991_050825.htm) ↗ |
| Q3 FY24CQ4 2023 | Dec 31, 2023 | 146.50 | -61.3% | SEC EDGAR Filing (exhibit991_013025.htm) ↗ |
| Q2 FY24CQ3 2023 | Sep 30, 2023 | 198.90 | -10.0% | SEC EDGAR Filing (exhibit991_103124.htm) ↗ |
| Q1 FY24CQ2 2023 | Jun 30, 2023 | 92.40 | +9.7% | SEC EDGAR Filing (exhibit991_072723.htm) ↗ |
| Q4 FY23CQ1 2023 | Mar 31, 2023 | 293.70 | – | SEC EDGAR Filing (exhibit991_050924.htm) ↗ |
| Q3 FY23CQ4 2022 | Dec 31, 2022 | 378.30 | – | SEC EDGAR Filing (exhibit991_020124.htm) ↗ |
| Q2 FY23CQ3 2022 | Sep 30, 2022 | 221.00 | – | SEC EDGAR Filing (exhibit991_102623.htm) ↗ |
| Q1 FY23CQ2 2022 | Jun 30, 2022 | 84.20 | – | SEC EDGAR Filing (exhibit991_072723.htm) ↗ |
Cite this data
StockData. (2026). Takeda Pharmaceutical Net Cash from Operating Activities (Operating Cash Flow, quarterly Q1 FY23–Q2 FY27 [Data set]. Compiled from Takeda Pharmaceutical SEC filings and investor materials. https://stockdatahq.com/stocks/tak/kpis/sec-ocf
See every metric in the Takeda Pharmaceutical KPI table. Data updated Nov 10, 2026.
See a number that looks wrong?